07:00 , Mar 19, 2012 |  BC Week In Review  |  Clinical News

SCYX-7158: Phase I started

Anacor said the Drugs for Neglected Diseases initiative (Geneva, Switzerland) began a double-blind, placebo-controlled, French Phase I trial to evaluate single and multiple ascending-doses of oral SCYX-7158 in up to 120 healthy male volunteers. The...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

Anacor preclinical data

In a mouse model of stage 2 human African trypanosomiasis, once-daily 12.5 and 25 mg/kg oral SCYX-7158 given over 7 days starting on day 21 post-infection produced cure rates of 80% and 100%, respectively. Cure...